Pimozide could be a promising drug to overcome taxane cabazitaxel (CBZ) resistance in docetaxel-resistant prostate cancer (CRPC) patients by targeting AURKB and KIF20A [82]. The gene discussed is KIF20A; the disease is prostate carcinoma.